UPC Analytics
ENDE
Overview · Filed: Apr 9, 2024

UPC_CFI_165/2024

PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF

Provisional measuresProvisional MeasuresDusseldorf LDProvisional measuresCase Closed
OverviewDecisionsReasoningCitationsDocumentsTimeline
Parties

Claimants

  • Novartis AG
  • Genentech, Inc.
Reps: Frank-Erich Hufnagel (Freshfields Bruckhaus Deringer); Kilian Seidel (Freshfields Bruckhaus Deringer); Cameron Marshall (Carpmaels & Ransford); Joanna Rowley (Carpmaels & Ransford)

Respondents

  • Celltrion Healthcare Hungary Kft.
  • Celltrion Healthcare Deutschland GmbH
  • Celltrion Healthcare Belgium SPRL
  • Celltrion Healthcare France SAS
  • Celltrion Healthcare Finland Oy
  • Celltrion Healthcare Italy S.R.L.
  • Celltrion Healthcare Netherlands B.V.
Reps: (not specified) ((Celltrion representatives))
Judges
  • Berenice Thom
  • Berenice Thom
  • Alima Zana
  • John Petersen
Patents
  • EP3805248
  • EP 3 805 248 B1
CPC codes: B01D2311/04, A61K39/39591, B01D2311/16, B01D61/146, C07K16/065, C07K2317/21, C07K16/4291, C07K1/34, B01D61/16

Sector: Organic Chemistry

Outcome
PI denied
Filed: Apr 9, 2024
First decided: —
Language: English

Order of Düsseldorf Local Division rejecting Novartis/Genentech's application for provisional measures against Celltrion Healthcare entities regarding EP 3 805 248 B1 (biosimilar product Epysqli). The court found the requirements for provisional measures were not met and ordered Novartis/Genentech to pay interim costs of EUR 138,562.80. The court set out important headnotes on: the interpretation of Art. 25 and 62 UPCA as autonomous uniform law; the concept of imminent infringement; group company liability; inapplicability of R. 295 RoP to provisional measures applications; and parties' obligation to present focused technical arguments.

Open on UPC Registry